1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal

 
• By Sukaina Virji

Teva Pharmaceutical Industries Ltd. has signed an exclusive licensing agreement for Heptares Therapeutics' small-molecule calcitonin gene-related peptide (CGRP) antagonist program for the treatment of migraine. A wave of biologicals targeting the CGRP pathway are approaching late-stage development, but Heptares CEO Malcolm Weir believes that small molecule CGRP antagonists "present the opportunity for delivery using routes that are not available to biologics, such as oral or intra-nasal, and for patients with different needs, such as in acute therapy," he told Scrip.

Teva Pharmaceutical Industries Ltd. has signed an exclusive licensing agreement for Heptares Therapeutics' small-molecule calcitonin gene-related peptide (CGRP) antagonist program for the treatment of migraine. A wave of biologicals targeting the CGRP pathway are approaching late-stage development, but Heptares CEO Malcolm Weir believes that small molecule CGRP antagonists "present the opportunity for delivery using routes that are not available to biologics, such as oral or intra-nasal, and for patients with different needs, such as in acute therapy," he told Scrip.

"CGRP is a well validated target for migraine but getting good small molecules for it have proved difficult because it's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Biogen’s Spinraza Follow-On May Offer Disease-Modifying Potential

 
• By Joseph Haas

Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

More from Therapy Areas

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader

 
• By Andrew McConaghie

Zidesamtinib would be the fifth ROS-1 targeting therapy on the market, but Nuvalent believes its safety and efficacy profile will make it the best in class.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By Kevin Grogan

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

Battle For Obesity Market Shifts Gears in India: Will Wegovy Trump Mounjaro?

 
• By Anju Ghangurde

Novo Nordisk debuts Wegovy in India, gears for pole position in obesity. The Danish group’s leadership doesn’t appear too perturbed about the head start for Lilly’s Mounjaro or the imminent arrival of generic semaglutide next year.